Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

Core Insights - Axogen, Inc. will report its third quarter financial results for 2025 on October 29, 2025, before market opening, followed by a conference call at 8 a.m. ET [1] - The company specializes in innovative surgical solutions aimed at restoring peripheral nerve function, addressing the needs of patients with nerve damage [3] Company Overview - Axogen is a leader in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair, focusing on improving patients' quality of life [3] - The company offers a range of products designed to assist in the repair and protection of peripheral nerves, including Avance Nerve Graft and Axoguard Nerve Connector [4] Product Portfolio - Avance Nerve Graft: A processed human nerve allograft for bridging severed peripheral nerves without additional surgical sites [4] - Axoguard Nerve Connector: A porcine submucosa ECM coaptation aid for tensionless repair of severed nerves [4] - Axoguard Nerve Protector: Protects damaged nerves and reinforces reconstruction while minimizing soft tissue attachments [4] - Axoguard HA+ Nerve Protector: A next-generation product designed to enhance nerve gliding and provide protection for injuries [4] - Axoguard Nerve Cap: Protects nerve ends and reduces the development of painful neuromas [4] - Avive+ Soft Tissue Matrix: An amniotic membrane allograft used during tissue healing [4] Market Presence - Axogen's products are available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [4]